Dr. Wolf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
704 S Webster Ave
Green Bay, WI 54301Phone+1 920-338-6868Fax+1 920-338-6869
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Obstetrics and Gynecology, 1986 - 1990
Northeast Ohio Medical UniversityClass of 1986
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology
Certifications & Licensure
AZ State Medical License 2011 - 2026
GA State Medical License 2014 - 2026
NY State Medical License 2020 - 2026
TN State Medical License 2022 - 2026
VA State Medical License 2022 - 2026
IN State Medical License 2014 - 2025
MT State Medical License 2023 - 2025- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
- Join now to see all
Clinical Trials
- Gene Therapy in Treating Patients With Ovarian Cancer Start of enrollment: 1998 Sep 01
- PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2002 Jul 01
- Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2004 Sep 02
- Join now to see all
Publications & Presentations
PubMed
- Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.Lingegowda S. Mangala, Vesna Zuzel, Rosemarie Schmandt, Erik S. Leshane, Jyotsna B. Halder
Clinical Cancer Research. 2021-08-01 - 4 citationsPhase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancerAnca Chelariu-Raicu, Charles F Levenback, Brian M. Slomovitz, Judith K. Wolf, Diane C. Bodurka
International Journal of Gynecological Cancer. 2020-10-09 - 3 citationsPhase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.Brian M. Slomovitz, Anca Chelariu-Raicu, Kathleen M. Schmeler, Karen H. Lu, David M. Gershenson
International Journal of Gynecological Cancer. 2020-10-05
Press Mentions
Provista Diagnostics Appoints Judith K. Wolf, M.D., as Chief Medical OfficerJuly 28th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
